Synthesis of new hypoxia markers EF1 and [18F]-EF1.
A V Kachur, W R Dolbier, S M Evans, C Y Shiue, G G Shiue, K A Skov, I R Baird, B R James, A R Li, A Roche, C J Koch
Index: Appl. Radiat. Isot. 51(6) , 643-50, (1999)
Full Text: HTML
Abstract
We report on the preparation of a hypoxia marker 2-(2-nitroimidazol-1[H]-yl)-N-(3-fluoropropyl)acetamide (EF1) and its 18F analog, 2-(2-nitroimidazol-1[H]-yl)-N- (3-[18F]fluoropropyl)acetamide ([18F]-EF1). Two methods for the preparation of 3-fluoropropylamine, the EF1 side chain, are described. [18F]-EF1 was prepared with a radiochemical yield of 2% by nucleophilic substitution of bromine in 2-(2-nitroimidazol-1[H]-yl)-N-(3-bromopropyl)acetamide (EBr1) by carrier-added 18F in DMSO at 120 degrees C. Our results demonstrate the preparation of clinically relevant amounts of [18F]-EF1 for use as a non-invasive hypoxia marker with detection using positron emission tomography (PET).
Related Compounds
Related Articles:
1998-08-01
[Talanta 46 , 1095-1105, (1998)]
2003-04-01
[Anal. Bioanal. Chem 375 , 1229-1233, (2003)]
2004-09-08
[Talanta 64 , 230-236, (2004)]
2012-02-29
[J. Hazard. Mater. 205-206 , 10-16, (2012)]
2001-08-24
[FEBS Lett. 504(1-2) , 45-9, (2001)]